Loading
Led CheckMate 649, which made immunotherapy plus chemotherapy the first-line standard for gastric cancer, and the pembrolizumab-trastuzumab combination in HER2-positive disease.
Yelena Y. Janjigian is Chief of the Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center. She is a gastrointestinal oncologist known for leading CheckMate 649, which made nivolumab plus chemotherapy the first-line standard for gastric cancer, and KEYNOTE-811, which established pembrolizumab with trastuzumab in HER2-positive disease. Her selected papers report first-line nivolumab plus chemotherapy in advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma, and the KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Her research programme focuses on HER2 and immune biomarkers in gastro-oesophageal cancer.
Shares CheckMate 649, CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma, Oesophageal cancer, Nivolumab.
Shares KEYNOTE-811, Trastuzumab, Pembrolizumab.
Shares CheckMate 649, HER2, Nivolumab, PD-1.
Shares Trastuzumab, HER2, Nivolumab, PD-1.
Shares Trastuzumab, HER2, Oesophageal cancer, PD-1.
Shares CheckMate 649, Gastric & gastro-oesophageal junction cancer.
Shares Trastuzumab, HER2, PD-1, Gastric & gastro-oesophageal junction cancer.
Shares Trastuzumab, HER2, PD-1, Pembrolizumab.